Hypertrophic Cardiomyopathy in Iran: General Characteristics, Clinical Presentations, Imaging Features, and Major Adverse Cardiovascular Events of 322 Patients
This study showed the general characteristics, clinical outcomes, and therapeutic approach of HCM patients in Iran. We found more MACE in obstructive versus nonobstructive forms and LGE ≥ 10%. Disopyramide and implantable cardioverter-defibrillator implantation are well-adapted therapeutic options, followed by surgical myectomy. However, genetic testing and alcohol septal ablation are uncommon procedures.
Authors
- Saman Rostambeigi (ORCID: https://orcid.org/0000-0002-6342-5714)
- Anita Sadeghpour (ORCID: https://orcid.org/0000-0002-8485-0058)
- Negin Mahmoudi Hamidabad (ORCID: https://orcid.org/0000-0003-2590-2943)
- Erfan Hashemi (ORCID: https://orcid.org/0000-0002-9119-5143)
- Hamidreza Pouraliakbar (ORCID: https://orcid.org/0000-0002-2557-4030)
- Azin Alizadehasl (ORCID: https://orcid.org/0000-0002-8550-1378)
- Sarah Nadri
Institutions
- Iran University of Medical Sciences (IR)
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
- Rasool Akram Hospital (IR)
- Shaheed Rajaei Cardiovascular Medical and Research Center (IR)
- Babol University of Medical Sciences (IR)
- MedStar Health (US)
Publication Details
- Journal
- Heart Views
- Published
- 2025-04-01
- DOI
- https://doi.org/10.4103/heartviews.heartviews_155_24
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00